|1.||Convertino, Victor A: 14 articles (08/2015 - 07/2002)|
|2.||Benditt, David G: 13 articles (06/2015 - 03/2003)|
|3.||Brignole, Michele: 11 articles (07/2015 - 01/2003)|
|4.||Kenny, Rose Anne: 10 articles (08/2015 - 04/2002)|
|5.||Krahn, Andrew D: 10 articles (06/2015 - 07/2002)|
|6.||Del Rosso, A: 10 articles (04/2014 - 01/2000)|
|7.||Wieling, Wouter: 10 articles (01/2013 - 03/2003)|
|8.||Brignole, M: 10 articles (10/2007 - 01/2000)|
|9.||Zareba, Wojciech: 9 articles (10/2015 - 04/2004)|
|10.||Priori, Silvia G: 9 articles (07/2012 - 07/2002)|
|1.||Propranolol (Inderal)FDA LinkGeneric
08/01/2003 - "Both complete or partial efficacy of intravenous propranolol predict long-term efficacy of chronic beta blocker therapy in patients with vaso-vagal syncope."
01/01/2005 - "The survival analysis with respect to the recurrence of syncope revealed a significant correlation between the results of the tilt test with intravenously administered propranolol and the efficacy of the long-term beta-blocker therapy (P < 0.003). "
08/01/2003 - "Analysis of survival without a recurrence of syncope revealed a significant relationship between the results of tilt testing with intravenous propranolol and the efficacy of long-term beta-blocker therapy (p<0.003). "
08/01/1975 - "Treatment with propranolol was effective in abolishing the syncopal episodes, by reducing the post-tussive gradient and facilitating a more rapid return to normal of aortic pressure. "
02/01/2003 - "Intravenous propranolol occurred effective in preventing syncope during second TT in 29/37 (78%) patients. "
|2.||Midodrine (Midon)FDA LinkGeneric
09/23/2014 - "Five studies reported syncope recurrence in patients with RRS showing improvement with midodrine: risk difference 37% (95% CI 20.8%-47.4%), moderate confidence. "
12/01/2012 - "Rationale for the prevention of syncope trial IV: assessment of midodrine."
07/01/1999 - "Twenty-five patients (16 women, 9 men, mean age 30 +/- 23 years) with severe recurrent syncope and a positive head upright tilt table study (refractory to or intolerant of standard therapies) were placed on midodrine 5-10 mg orally three times per day, (two patients required 15 mg/day). "
11/01/2011 - "The median number of syncopes and pre-syncopes per 3 months were also not significantly different during Midodrine and placebo treatment (0 vs. 1; P= 0.57; and 6 vs. 8; P= 0.90). "
11/01/2011 - "The proportion of patients who experienced syncopal and pre-syncopal recurrences did not differ significantly between Midodrine and placebo treatment (syncope: 48 vs. 65%, P= 0.22; pre-syncope: 74 vs. 78%, P> 0.99). "
|3.||Lennox-Gastaut type Epileptic encephalopathyIBA
06/01/1993 - "3. In the 15 patients with Lennox-Gastaut syndrome, the drop attacks disappeared in 8 patients, and decreased in severity and frequency in 3 patients. "
09/01/2012 - "RUF seemed particularly effective in the prevention of myoclonic-astatic seizures (comparable with drop attacks in Lennox-Gastaut-Syndrome, for which RUF is particularly effective). "
06/01/2015 - "Later seizures may occur as specific patterns, such as in Lennox-Gastaut syndrome, or with combinations of seizures including focal and multifocal seizures, and drop attacks. "
06/01/2004 - "Some forms of generalized symptomatic epilepsy may also benefit from palliative surgical procedures (callosotomy in cases with repetitive drop attacks often as a manifestation of a Lennox-Gastaut syndrome). "
03/01/1997 - "Indeed, axial spasms, the most frequent type of drop attacks in the Lennox-Gastaut syndrome, probably do not have a cortical origin. "
|4.||Metoprolol (Lopressor)FDA LinkGeneric
09/15/1998 - "Intravenous metoprolol was found to be significantly more effective than placebo in preventing head-up tilt-table induced neurally mediated syncope. "
07/01/1997 - "Recurrent syncope in 4 patients was associated with either noncompliance or discontinuation of therapy in 3 patients; in 1 patient, increasing the dose of metoprolol was effective in preventing recurrences. "
03/01/1993 - "The efficacy of intravenous metoprolol in preventing symptoms during a repeat tilt test was compared with the outcome of chronic oral treatment in 21 patients (14 female, 7 male), age 8 to 20 years (mean 13 +/- 3) with unexplained syncope (> or = 1 episode) and a positive response to tilt testing. "
10/01/2012 - "A multivariable proportional hazards model stratified by center was performed on 208 participants in the randomized Prevention of Syncope Trial (POST), examining the interaction between age group and treatment with metoprolol. "
10/01/2009 - "Effect of metoprolol on quality of life in the Prevention of Syncope Trial."
04/01/1989 - "Thirty-nine consecutive patients with recurrent syncope and either cardioinhibitory or mixed type carotid sinus syndrome were studied to determine the efficacy of ventricular (VVI) pacing in 16, and dual chamber (DDD/DVI) in 23 patients. "
11/01/2012 - "Finally, we were urged to conduct implantation of a DDD pacemaker combined with ICD surgically with epicardial leads, resulting in successful suppression of TdP and syncope. "
01/01/2005 - "In the VVS patients with recurrent syncope and severe heart inhibition, DDD pacing with RDR function could prevent from syncope efficiently."
05/07/2003 - "The relative risk reduction in time to syncope with DDD pacing was 30% (95% CI, -33% to 63%; 1-sided P =.14). "
05/07/2003 - "The cumulative risk of syncope at 6 months was 40% (95% confidence interval [CI], 25%-52%) for the ODO group and 31% (95% CI, 17%-43%) for the DDD group. "
02/01/2011 - "Rufinamide was most effective in patients with drop-attacks and (bi)frontal spike-wave discharges."
01/01/2010 - "If society is prepared to pay at least 250 pounds for a 1% increase in the number of successfully treated LGS patients, in terms of a 50% reduction in the frequency of drop attacks, the probability of the treatment with rufinamide being cost effective is >80%. "
01/01/2010 - "Rufinamide appears to be especially effective for atonic or drop attack seizures. "
02/01/2007 - "In a randomized, double-blind trial involving 138 adult and pediatric patients with LGS, compared with placebo, rufinamide 45 mg/kg/day resulted in significantly superior reductions in drop attacks (median change -42.5% vs +1.4% with placebo) and total seizures (-32.1% vs -11.7% with placebo), accompanied by significantly higher responder rates. "
03/01/2012 - "The cost-effectiveness analysis suggested that rufinamide would be associated with incremental costs of £62 (drop attacks) or £2151 (total seizures) per 1% increase in the number of patients achieving a >50% reduction in seizure frequency over 3 years. "
|7.||Isoproterenol (Isoprenaline)FDA LinkGeneric
11/01/2000 - "Heart rate responses after isoproterenol infusion were significantly greater in the syncope group than in the nonsyncope group. "
01/01/2003 - "Although acute beta-blockade may prevent the development of syncope during isoproterenol tilt-table testing, the use of beta-blockers for chronic prophylaxis may not be effective for some patients who show a positive response to isoproterenol tilt-table testing. "
12/01/1996 - "As the proportion of patients with a positive isoproterenol tilt test was reported to decline with age, our results suggest that the reduced incidence of syncope during isoproterenol tilt testing could be the expression of impaired autonomic response among elderly syncope patients."
01/04/2006 - "isoproterenol infusion increased the sensitivity of EPS in patients with syncope, related or not to exercise, and with negative study in control state, but principally in those with HD. "
01/04/2006 - "The purpose of the study was to evaluate the interests of electrophysiologic study (EPS) after infusion of isoproterenol in patients with syncope and negative EPS in control state. "
|8.||Amiodarone (Amiodarona)FDA LinkGeneric
05/01/1987 - "ES was, therefore, of diagnostic value in more than half of the patients with syncope of unknown cause and long-term treatment based on ES was successful in the prevention of S (remission rate of 93% in patients treated with amiodarone or pacemaker)."
06/01/1981 - "A patient with the familial syndrome of Q-T prolongation, ventricular arrhythmias, and syncope was effectively treated with amiodarone."
12/01/1988 - "A standard dual chamber pacemaker with the ability to telemeter intracardiac electrograms and to perform noninvasive electrophysiological studies was implanted in a patient with previously documented complex ventricular arrhythmias treated with amiodarone who later presented with a hypersensitive carotid sinus syndrome and syncope. "
01/01/1981 - "While on amiodarone therapy, the patient experienced another syncopal episode and therefore a second electrophysiological study was done. "
04/01/2008 - "Syncope was associated with increased mortality risk in SCD-HeFT regardless of treatment arm (placebo, amiodarone, or ICD)."
|9.||Atenolol (Tenormin)FDA LinkGeneric
02/01/2001 - "Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study."
09/01/2000 - "Atenolol is effective for the prevention of provoked or spontaneous recurrent syncope or pre-syncope."
12/01/1995 - "Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results."
02/01/2001 - "The Kaplan-Meier actuarial estimates of time to first syncopal recurrence showed that the probability of remaining free of syncope drops similarly in both groups and that there was no statistical difference between both curves (patients treated with atenolol vs. the placebo) with a log-rank test p value of 0.4517. "
02/01/2001 - "In the intention-to-treat analysis, the group treated with atenolol had a similar number of patients with recurrent syncopal episodes as the placebo group. "
|10.||topiramate (Topamax)FDA LinkGeneric
06/10/1999 - "Topiramate adjunctive therapy was effective in reducing the number of drop attacks and major motor seizures and in improving seizure severity as determined by parental global evaluation."
06/10/1999 - "The percentage of patients with a > or = 50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was greater in the topiramate group (15/46 or 33%) than in the control group (4/50 or 8%; p = 0.002). "
06/10/1999 - "For drop attacks, the most severe seizures associated with this syndrome, the median percentage reduction from baseline in average monthly seizure rate was 14.8% for the topiramate group and -5.1% (an increase) for the placebo group (p = 0.041). "
06/10/1999 - "Ninety-eight patients >1 year to <30 years of age, with slow spike-and-wave patterns on EEG, seizure types including drop attacks, and either a history of or active atypical absence seizures, were assigned to an 11-week, double-blind treatment phase with either topiramate or placebo. "
07/01/2004 - "However, because carbamazepine failed to control the head drop attacks, topiramate was also included, and the attacks were kept under control with topiramate. "
|1.||Drug Therapy (Chemotherapy)
10/01/2010 - "The patient who failed pharmacotherapy received a dual-chamber closed-loop pacemaker and subsequently reported marked improvement in her symptoms with elimination of her syncope. "
10/31/2009 - "Six months after 3 cycles of chemotherapy, he remained in complete remission and resolution of syncope. "
12/01/2012 - "Outcome is related to previous attack frequency for patients with VVS, physical therapy is effective for reducing the recurrence rate of syncope in VVS patients with low attack frequency while physical therapy combined with pharmacotherapy should be applied for VVS patients with high attack frequency to improve outcome."
08/01/1997 - "Because the natural history of neurocardiac syncope in children is spontaneous resolution, it is appropriate to try the simple measures before introducing drug therapy."
05/01/1993 - "In addition to its diagnostic ability, tilt table testing may provide a means to assess the efficacy of preventive pharmacotherapy for syncope. "
|2.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
10/01/2007 - "These patients suffered from syncopal episodes, exhibited a positive electrophysiological study, and finally received an implantable cardioverter-defibrillator. "
03/01/2015 - "While implantable defibrillators prolong survival, many patients remain symptomatic due to device shocks and syncope. "
01/01/2015 - "Implantable cardiac electronic devices, including implantable loop recorders (ILR) and implantable cardioverter-defibrillators (ICD), are well established in syncope management. "
02/01/2014 - "This systematic review and meta-analysis assessed the relationship between therapy reduction programming with the risks of death from any cause, implantable cardioverter defibrillator shocks, and syncope. "
07/01/2013 - "Due to the recurrence of syncopes despite the presence of beta-blockers, an implantable cardioverter defibrillator was implanted. "
11/01/2015 - "Radiotherapy-induced Recurrent Syncope."
12/13/1996 - "Exercise-induced syncope as late consequence of radiotherapy."
09/22/1984 - "A 58 year old man developed episodes of syncope after surgery and radiotherapy for a laryngeal tumour. "
03/01/2000 - "Treatment of carcinoma by chemotherapy and radiotherapy promptly eliminated the syncopal episodes. "
09/01/2011 - "We report the case of a 76-year-old man who suffered from recurrent syncope due to invasion of the right carotid sinus by metastases of a carcinoma of the esophagus, successfully treated by radiotherapy. "
09/01/1990 - "The mean age of patients for studies that reported age data was 36 years, with a male-to-female ratio of 2.5 to 1. Over 90% of the patients required resuscitation, while syncope due to nonsustained VF occurred in the rest. "
10/01/2011 - "Owing to recurrent worsening symptoms and a syncopal episode requiring resuscitation, an echocardiogram was performed. "
10/01/2005 - "Death, syncope, resuscitation, and dysrhythmias during transport or immediately on arrival to the floor were the outcomes measured. "
08/01/1993 - "After a mean follow-up of 13 months, three of the four patients had appropriate discharges without syncope or resuscitation. "
12/01/1955 - "[An empirical method for cardiac resuscitation in Stokes-Adams syncope disease]."
11/01/2013 - "Rates of syncope increased with the number of injections received per immunization episode. "
03/01/2003 - "Fear of injections was common in this cohort and was highly associated with past fainting after vaccination."
09/07/1998 - "Multivariate genetic analyses were used to examine the genetic and environmental contributions to individual differences in fears of blood, injury, and injections in 659 twin pairs who completed questions concerning fear and fainting around blood, injury, and injections, and fainting in situations not involving blood, as well as the personality scales of Neuroticism, and Harm Avoidance. "
05/01/1997 - "fear or fainting) about blood or injections completed the BISS. "
04/01/1996 - "The single factor, "fear of injections and blood draws" accounted for the majority of the MFS prediction of fainting, correctly classifying 72% of the fainters and 47% of non-fainters. "